

# *Acta Medica Okayama*

---

*Volume 54, Issue 2*

2000

*Article 2*

APRIL 2000

---

## Purification, identification and phosphorylation of annexin I from rat liver mitochondria.

Kenji Yoshii\*

Katsuyoshi Sugimoto<sup>†</sup>

Yuji Tai<sup>‡</sup>

Ryoji Konishi\*\*

Masaaki Tokuda<sup>††</sup>

\*Kagawa Medical University,

<sup>†</sup>Kagawa Medical University,

<sup>‡</sup>Kagawa Medical University,

\*\*Kagawa Medical University,

<sup>††</sup>Kagawa Medical University,

# Purification, identification and phosphorylation of annexin I from rat liver mitochondria.\*

Kenji Yoshii, Katsuyoshi Sugimoto, Yuji Tai, Ryoji Konishi, and Masaaki Tokuda

## Abstract

Annexin was purified from rat liver mitochondria to an apparent homogeneity with a molecular weight of 35 kDa as determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis. The purified mitochondrial annexin (AXmito) was identified as annexin I by an immunoblot analysis using anti-annexin I antibody. The inhibitory effect of AXmito I on porcine pancreatic phospholipase A2 activity was as potent as that of bovine lung annexin I. The presence of annexin I in mitochondria was confirmed by an electron-microscopic study. AXmito I was shown to be phosphorylated by intrinsic protein tyrosine kinases on its tyrosine residues. This annexin was also phosphorylated by protein kinase C.

**KEYWORDS:** annexin, mitochondria, protein tyrosine kinases, protein kinase C, Phospholipase A2

# Purification, Identification and Phosphorylation of Annexin I from Rat Liver Mitochondria

Kenji YOSHII<sup>ac</sup>, Katsuyoshi SUGIMOTO<sup>a</sup>, Yuji TAI<sup>a</sup>, Ryoji KONISHI<sup>b</sup> and Masaaki TOKUDA<sup>a\*</sup>

<sup>a</sup>Departments of Physiology and <sup>b</sup>Pharmaco-Bio-Informatics, Faculty of Medicine, Kagawa Medical University, Kagawa 761-0793, Japan and <sup>c</sup>Mizushima Kyodo Hospital, Okayama 712-8024, Japan

Annexin was purified from rat liver mitochondria to an apparent homogeneity with a molecular weight of 35kDa as determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis. The purified mitochondrial annexin (AXmito) was identified as annexin I by an immunoblot analysis using anti-annexin I antibody. The inhibitory effect of AXmito I on porcine pancreatic phospholipase A<sub>2</sub> activity was as potent as that of bovine lung annexin I. The presence of annexin I in mitochondria was confirmed by an electron-microscopic study. AXmito I was shown to be phosphorylated by intrinsic protein tyrosine kinases on its tyrosine residues. This annexin was also phosphorylated by protein kinase C.

**Key words:** annexin, mitochondria, protein tyrosine kinases, protein kinase C, phospholipase A<sub>2</sub>

**A**n nexins (also called lipocortins) are widely distributed in eukaryotic cells, and at least 13 structurally related proteins have been identified to date and studied in many cells and tissues (1-5). In addition other related proteins such as chromobindins (6), calcimedins (7), endonexins (8), calelectrins (9), calpactins (10), and proteins I-III (11) have also been described by many laboratories. Annexins have been implicated in cellular differentiation and cell growth (12-14), inflammation and glucocorticoid action (15-17, 18), interaction to actin and spectrin (19, 20), and secretion and exocytosis (21-23). We have also shown that annexin I is involved in the pathogenesis of human hepatocellular carcinomas (24). The anti-inflammatory action of annexins is attributed to their inhibitory activity on phospholipase A<sub>2</sub> (PLA<sub>2</sub>), a Ca<sup>2+</sup>-dependent enzyme producing arachidonic acid from membrane phospholipids, although there exists some

controversy regarding this inhibition (25, 26). We previously reported that 3 types of annexins have the ability to inhibit to some extent PLA<sub>2</sub> activity *in vitro* (27, 28). Another characteristic of annexins is their susceptibility to phosphorylation by several protein tyrosine kinases (PTKs) (29, 30) or by Ca<sup>2+</sup>-phospholipid-dependent protein kinase (C-kinase) (28).

We have studied the coupling mechanisms between mitochondrial functions and their configurational changes, and successfully demonstrated the existence of calmodulin, other Ca<sup>2+</sup>-binding proteins, and actin in mitochondria (31-33). PLA<sub>2</sub> is present in mitochondria and plays an important role in mitochondria's configurational changes induced by phospholipid hydrolysis (32, 34-36). The presence of both actin and PLA<sub>2</sub> in mitochondria suggested the possibility that annexins may be present in mitochondria and regulate PLA<sub>2</sub> or actin-polymerization. The typical purification procedure (28) for annexins allowed us to purify mitochondrial annexin (AXmito).

In the present report, we describe the purification of AXmito and several of its properties, such as immunoreactivity against anti-annexin antibodies, anti-PLA<sub>2</sub> activity, and phosphorylation by PTKs and C-kinase.

## Materials and Methods

**Materials.** Anti-annexin I and II antibodies were kindly provided by Dr. RB Pepinsky (Biogen Res. Co., MA, USA). Bovine lung annexins I and II were purified according to Khanna *et al.* (28). Anti-phosphotyrosine antibody was purchased from Amersham (Tokyo). Protein A-conjugated Sepharose 4B and Percoll were purchased from Pharmacia (Tokyo). Radioisotopes were obtained from Japan Radioisotope Association (Tokyo).

---

\* To whom correspondence should be addressed.

Angiotensin II, and porcine pancreatic phospholipase A<sub>2</sub> were from Sigma Chemical Co. (Tokyo). Other chemicals were purchased from Wako Pure Chemical Ltd. (Osaka).

**Purification of annexin from rat liver mitochondria.** Crude mitochondria were purified from rat liver using the conventional differential centrifugation method, and washed 3 times with buffer A (0.25 M sucrose, 40 mM Tris-HCl [pH 7.4], 1 mM dithiothreitol [DTT], 3 mM benzamidine, 50  $\mu$ M phenylmethylsulfonylfluoride [PMSF], 1  $\mu$ g/ml leupeptin, and 1 mM EGTA [ethylene glycol bis ( $\beta$ -aminoethylether) N,N,N',N'-tetraacetic acid]). The mitochondria were then suspended in 33% (v/v) Percoll solution in buffer A, and centrifuged at 40,000  $\times g$  for 30 min without electric braking (37). The purified mitochondria were suspended in hypotonic buffer B (20 mM Tris-HCl [pH 7.4], 1 mM DTT, 3 mM benzamidine, 1  $\mu$ g/ml leupeptin, and 1 mM CaCl<sub>2</sub>), and sonicated at 19.5 KHz 1 mA for 30 sec with type T-A 4280 Ultrasonicator (Kaijo Denki, Tokyo). After removing the unbroken mitochondria by centrifugation at 8,500  $\times g$  for 10 min, the supernatant was centrifuged at 105,000  $\times g$  for 70 min to separate the soluble matrix and membrane fractions. The membrane fraction was then washed 3 times with buffer B. To extract annexin from membrane, buffer C (containing 1 mM EGTA instead of CaCl<sub>2</sub> in buffer B) was added to the membrane fraction and homogenized using a teflon homogenizer. After centrifugation at 105,000  $\times g$  for 70 min, the supernatant was collected as an annexin fraction. For further purification of annexins from this fraction, anion-exchange chromatography (DEAE-Sephacel, Pharmacia), high performance liquid chromatography (HPLC) gel permeation chromatography (TSKgel G3000SW, TOSOH, Tokyo), and HPLC cation-exchange chromatography (TSKgel CM-3SW) were performed according to methods previously described (28). At each step, the fraction was analyzed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) to examine the annexin's purity.

**Phospholipase A<sub>2</sub> assay.** PLA<sub>2</sub> assay was performed according to Khanna *et al.* (27) using porcine pancreatic PLA<sub>2</sub> as the enzyme and L- $\alpha$ -palmitoyl-2-[<sup>14</sup>C]oleyl phosphatidyl-choline as a substrate.

**Assay of protein tyrosine kinase activity.** The phosphorylation reaction was carried out according to the method previously described (38). The reaction

medium contained 40 mM 3-[N-Morpholino] propanesulfonic acid [pH 7.4], 5 mM MgCl<sub>2</sub>, 1 mM DTT, 7 mM p-nitrophenyl-phosphate, 1  $\mu$ g/ml leupeptin, and 1 mM angiotensin II as a substrate. The reaction was initiated by the addition of [ $\gamma$ -<sup>32</sup>P] ATP (5  $\mu$ Ci/ml) at a final concentration of 50  $\mu$ M ATP, and was terminated by the addition of phosphoric acid after incubation for 30 min at 30 °C.

**Phosphorylation of mitochondria.** Pure mitochondria were suspended in buffer A, and the phosphorylation reaction was started by adding <sup>32</sup>P-labeled ortho-phosphate (<sup>32</sup>Pi, 0.5 mCi/ml) at a concentration of 0.2 mM. Mitochondria were centrifuged and washed 3 times with buffer A to remove unincorporated free <sup>32</sup>Pi. Phosphopeptides were analyzed by SDS-PAGE (12.5% uniform or 7.5–20% gradient acrylamide gels). Gels were treated with 1N KOH for 2 h at 55 °C in order to hydrolyze phosphoserine or phosphothreonine residues, and then dried. Autoradiographic analysis was performed to demonstrate the presence of alkaline-resistant phosphorylation of peptides.

**Phosphorylation of annexin by C-kinase.** C-kinase was purified from bovine brain as described by Kikkawa *et al.* (39), and phosphorylation by C-kinase was performed as described previously (28).

**Immunoprecipitation analysis.** Phosphorylated mitochondria were solubilized with 0.5% Triton X-100 in buffer A and incubated with anti-annexin I antibody for 12 h at 4 °C to precipitate annexin I. The antigen-antibody complex was absorbed by Protein A-conjugated Sepharose 4B beads for 2 h at room temperature. The beads were collected by centrifugation and washed thoroughly with 40 mM Tris-HCl buffer [pH 7.4] containing 150 mM KCl, 0.5% Tween-20, and 1 mM DTT, and then boiled in SDS-PAGE sample buffer. After SDS-PAGE, autoradiographic analysis was performed to demonstrate the precipitated phosphopeptides.

**Phosphoamino acid analysis.** Phosphoamino acid analysis was performed according to the method previously described (40). Phosphorylated peptide (not alkaline-treated) was cut from SDS-PAGE and electro-eluted with 2% agarose gel. Partial acid hydrolysis was performed and phosphoamino acids were separated on a cellulose plate by electrophoresis (1,000 V, 60 min) at pH 3.5 (pyridine/acetic acid/water [1:10:189, v/v]). Marker phosphoamino acids were phosphotyrosine (p-Tyr), phosphothreonine (p-Thr), and phosphoserine (p-Ser), identified by ninhydrin staining.

Autoradiography was carried out on Kodak X-Omatic AR film.

**Immunoblot analysis.** Immunoblot analysis using anti-annexin I and II antibodies was performed according to the method previously described (28). Bovine lung annexins I and II were used as positive standards for the reaction.

**Immunoelectron microscopy.** Immunoelectron microscopy was performed as previously described (33).


**Others.** SDS-PAGE was performed according to Laemmli (41). Protein concentration was measured by the method of Bradford (42) using bovine serum albumin as a standard.

## Results

### *Purification and characterization of annexin from rat liver mitochondria.* Percoll-

purified mitochondria were separated into matrix and membrane fractions in the presence of 1 mM  $\text{CaCl}_2$ , and the membrane fraction was collected and washed extensively by centrifugation. A millimolar concentration of calcium ions allows annexins to associate to the membrane, and this protein can then be easily extracted by the addition of EGTA, a  $\text{Ca}^{2+}$ -chelator. Several peptide bands were observed in this extract on SDS-PAGE pattern as shown in Fig. 1A (lane b). An annexin-like peptide was purified to an apparent homogeneity with a molecular weight of 35kDa (lane c) using the typical method for annexins (28). The molecular weight of the AXmito was identical to bovine lung annexin I (lane d) and was smaller than bovine lung annexin II (lane e). From 100 g of rat liver, 10–15  $\mu\text{g}$  of AXmito were purified.

An immunoblot analysis using anti-annexin I and II antibodies was performed (Fig. 1B). The purified peptide was immuno-reacted with anti-annexin I antibody but not



**Fig. 1** Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and Western blot analysis of mitochondrial annexin (AXmito). **A:** SDS-PAGE analysis was performed as described in "Materials and Methods". Lane a, molecular weight markers in daltons (phosphorylase b, 94,000; bovine serum albumin, 67,000; ovalbumin, 43,000; carbonic anhydrase, 30,000; soybean trypsin inhibitor, 20,100); lane b, ethylene glycol bis ( $\beta$ -aminoethylether) N, N, N', N'-tetraacetic acid-extract from mitochondrial membrane fraction; lane c, purified AXmito after high performance liquid chromatography-carboxy-methyl chromatography; lane d, purified bovine lung annexin I; lane e, purified bovine lung annexin II.

**B:** Western blot analysis was performed as described in "Materials and Methods". The first antibody used was either anti-annexin I antibody (AXI) or anti-annexin II antibody (AXII). Lane a, bovine lung annexin I; lanes b and d, AXmito; lane c, bovine lung annexin II.


with anti-annexin II antibody.

To confirm the presence of annexin I in rat liver mitochondria, an immunoelectron-microscopic study using anti-annexin I antibody was performed (Fig. 2). About 90 % of immunoreactive gold particles for annexin I were located in mitochondria (Fig. 2b). Most of the particles were located in the membranous structures and a few in the matrix. Only a few particles were observed when pre-immune serum and anti-annexin II antibody were used

(Figs. 2a and 2c, respectively).

**Anti-PLA<sub>2</sub> activity of mitochondrial annexin.** We examined the inhibitory effect of AXmito on PLA<sub>2</sub> activity *in vitro* using 50 ng of porcine pancreatic PLA<sub>2</sub> as a target enzyme and 1 nmole of L- $\alpha$ -palmitoyl-2-[<sup>14</sup>C] oleyl phosphatidylcholine as a substrate. As shown in Fig. 3, AXmito was as potent as bovine lung annexin I in inhibiting PLA<sub>2</sub> activity.

**Presence of protein tyrosine kinases in**



**Fig. 2** Immunoelectron microscopic analysis of annexin I in rat liver mitochondria.

Percoll-purified mitochondria were subjected to immunoelectron microscopic analysis as described in "Materials and Methods". Pre-immune rabbit serum (a), anti-annexin I antibody (b) and anti-annexin II antibody (c) were used as the first antibody. Gold particle-conjugated anti-rabbit IgG was used as the second antibody. Bars in the figure indicate 0.5  $\mu$ m.

**Table I** Protein tyrosine kinase (PTK) activity<sup>a)</sup> in rat liver mitochondria

Fractions	Specific activity <sup>b)</sup> (cpm/mg protein/min)	Protein (mg)	Total activity (cpm)	Yield (%)
Crude mitochondria	486	362	176,000	100
Percoll-purified mitochondria	392	258	72,500	57.4
Membrane fraction	426	96	40,900	23.2
Matrix fraction	86	105	9,030	5.1

*a* : PTK activity was measured by the method described in the "Materials and Methods".

*b* : Specific activity was estimated as the amount of incorporated <sup>32</sup>P-labeled ortho-phosphate (<sup>32</sup>Pi, cpm) in angiotensin II for 1 min by PTKs contained in 1 mg protein of each fraction.

**mitochondria.** Another property of annexin is its susceptibility to phosphorylation by several PTKs such as pp60<sup>v-src</sup> (29) and epidermal growth factor receptor kinase (30). As shown in Table 1, PTK activity in mitochondria was shown using angiotensin II as a substrate. There was PTK activity in the crude mitochondrial fraction, and after washing 3 times with buffer A and subsequent Percoll purification, about 60% of the activity was retained in mitochondria. This activity was not significantly reduced by further washing with buffer A, and the membrane fraction was shown to contain 4 times higher PTK activity than the matrix fraction.

**Phosphorylation of mitochondrial annexin by intrinsic PTKs.** Intact mitochondria were incubated with <sup>32</sup>Pi in buffer A. Mitochondria were then solubilized and analyzed by SDS-PAGE. When succinate was added as a substrate for the Krebs cycle, tyrosine-phosphorylation of 2 peptides (about 300kDa and 35kDa) occurred (Fig. 4, right panel). Both peptides were phosphorylated at 15 min. The 300kDa peptide was quickly dephosphorylated by 85% at 30 min and by 100% at 45 min. In contrast, 2.4 fold phosphorylation of 35kDa peptide occurred at 30 min and then dephosphorylation occurred gradually, and even after 60 min, about 25% of the maximum phosphorylation level (at 30 min) was retained. The fact that no other major tyrosil-phosphorylated bands were seen indicates that annexin I in mitochondria was the major substrate for mitochondrial PTKs. When succinate was not added, almost no phosphorylation was observed except for a trace phosphorylation of 35kDa peptide at 15 min (Fig. 4, left panel).


Immunoprecipitation experiment using anti-annexin I antibody revealed that the precipitated peptide was phosphorylated (Fig. 5A, lane b) and the phosphorylation was resistant to alkaline treatment (Fig. 5A, lane c). The 35kDa phosphopeptide was then extracted from a non-alkaline treated gel, and a phosphoamino acid analysis was performed. Autoradiography demonstrated that only tyrosine residue was phosphorylated (Fig. 5B).

**Phosphorylation of mitochondrial annexin by C-kinase.** Purified AXmito was phosphorylated by C-kinase as shown in Fig. 5C. AXmito was strongly phosphorylated by C-kinase in the presence of Ca<sup>2+</sup> and phospholipid (lane b); however, no phosphorylation was observed in their absence (lane a).

## Discussion


An annexin was purified from rat mitochondria to an apparent homogeneity and identified as annexin I based on the following evidence: (a) the apparent molecular weight of the purified protein was 35kDa which is identical to annexin I from bovine lung preparation (Fig. 1A); (b) the protein was immunologically recognized by anti-annexin I antibody but not by anti-annexin II antibody (Fig. 1B); (c) an inhibitory effect of the purified protein on PLA<sub>2</sub> activity *in vitro* was as potent as that of bovine lung annexin I (Fig. 3), and (d) the protein was tyrosine-phosphorylated by endogenous PTKs (Figs. 5A, 5B), and also phosphorylated by C-kinase (Fig. 5C).

One might argue that cytosolic annexin I was co-



**Fig. 3** Anti-phospholipase A<sub>2</sub> (PLA<sub>2</sub>) activity of mitochondrial annexin (AXmito).

PLA<sub>2</sub> activity was assayed using the method described in "Materials and Methods". The reaction mixture contained 50 ng of porcine pancreatic PLA<sub>2</sub> and 1 nmole of L- $\alpha$ -palmitoyl-2-[<sup>14</sup>C] oleoyl phosphatidylcholine (approximately 20,000 dpm). A specific amount of bovine lung annexin I (Bov. Lung AXI, ○) or AXmito (■) was added to the reaction mixture 10 min before the addition of the substrate, and the reaction was started by the addition of labeled substrate and incubated for 30 min at 6 °C. Percent inhibition indicates [(PLA<sub>2</sub> activity without annexin) - (PLA<sub>2</sub> activity with annexin)] ÷ [(PLA<sub>2</sub> activity without annexin)] × 100. All average values and standard deviations were calculated by 3 different experiments.



**Fig. 4** Time course analysis of alkaline-resistant phosphopeptides in mitochondria.

Whole mitochondria were incubated with  $^{32}\text{P}$ i (0.5 mCi/ml) at 37 °C in the buffer A as described in "Materials and Methods", and the reaction was terminated each time by boiling in SDS-PAGE sample buffer. After SDS-PAGE analysis, the gel was stained and then treated with 1N KOH for 2 h at 55 °C, and was subjected to autoradiography. Molecular weight markers were the same as those used in Fig. 1A except for myosin (200,000) and  $\alpha$ -lactalbumin (14,300). Left panel, without succinate; right panel, with succinate (2 mM).

$^{32}\text{P}$ i; SDS; PAGE, see legends to Table I and Fig. 1.

purified with mitochondria preparation. The mitochondria used for this study were washed at least 3 times in the presence of EGTA, and were further purified using the Percoll gradient method. The fact that both annexin I and II immunoreactivities were present in the 100,000 xg hepatocyte supernatant (data not shown), while only annexin I and not annexin II was detected in mitochondria (both EGTA extract and HPLC-CM-purified fractions: blotting data using anti-annexin II antibody not shown) indicates that the possibility of contamination of cytosolic annexins during the purification steps can be excluded. Furthermore, an immunoelectron microscopic analysis (Fig. 2) elucidated that annexin I was present in mitochondria and existed in trace amounts in contaminated structures such as microsomes.

Since 1 mM  $\text{CaCl}_2$  was present at the beginning of the

purification procedure for annexins to bind to membrane,  $\text{Ca}^{2+}$ -dependent proteases could have been active during the purification procedure, and it is possible that the protein was proteolyzed by these proteases. It is, therefore, very crucial to add leupeptin, a potent  $\text{Ca}^{2+}$ -dependent protease inhibitor, as well as other inhibitors such as benzamidine and PMSF to the preparation medium. Otherwise, proteolytic degradation would yield peptides with smaller molecular weights (30–34kDa, data not shown).

When the purified AXmito was applied on a HPLC gel-permeation chromatography column, it was eluted between ovalbumin (45kDa) and  $\alpha$ -chymotrypsinogen A (24kDa), indicating that this protein existed as a monomeric form (data not shown). We did not detect any 11kDa peptide, which is a subunit of annexin-85 (28), by SDS-PAGE analysis of the purified protein.


It is unlikely that AXmito is coded in mitochondrial DNA because the entire sequence of mitochondrial DNA has been identified and no region provides for annexin. This fact suggests that annexin may be transported into mitochondria from cytosol. The possible mechanism of transport remains to be elucidated.

Annexins have been reported to have a potent inhibitory effect on  $\text{PLA}_2$  activity (27, 28). AXmito was shown to be as potent as bovine lung annexin I on  $\text{PLA}_2$  inhibition (Fig. 3), although the inhibitory action on pancreatic  $\text{PLA}_2$  *in vitro* may not be a physiological function (26). Mitochondrial  $\text{PLA}_2$  has been reported to be involved in mitochondrial configurational changes by altering ion or water permeability due to hydrolysis of membrane phospholipids (32, 34–36). AXmito I may have a role in the regulation of mitochondrial  $\text{PLA}_2$ .

Another possible role of annexin is to control actin-polymerization, although this has not been fully established (19, 20). We have demonstrated the existence of mitochondrial actin and its ability to polymerize (33). These data suggest that mitochondrial actin might be a cytoskeleton-like component involved in the configurational changes in mitochondria. AXmito may also regulate the configuration of mitochondria by affecting some intra-mitochondrial structure, possibly by its actin-binding property.

The evidence that PTK is present in mitochondrial membrane fraction supports the findings of Piedimonte *et al.* (43) who reported that PTK activity is localized in the outer mitochondrial membrane. According to our data, they might have detected both membrane-associated and





**Fig. 5** Phosphorylation of mitochondrial annexin (AXmito) I by protein tyrosine kinase and C-kinase.

**A:** Immunoprecipitation analysis of phosphorylated mitochondria using anti-annexin I antibody. Phosphorylated mitochondria were solubilized with 0.5% Triton X-100 containing buffer and incubated using control pre-immune rabbit serum (lane a) and anti-annexin I antibody (lane b) for 12 h at 4 °C as described in "Materials and Methods". Antigen-antibody complexes were adsorbed to protein A-conjugated Sepharose 4B beads and then solubilized with sample buffer for SDS-PAGE analysis. Following SDS-PAGE analysis, the gel was stained and analyzed autoradiographically. The gel of lane b was then cut and treated with 1N KOH for 2 h at 55 °C, and was subjected to autoradiography (lane c). Arrowhead indicates AXmito. Molecular weight markers were the same as those in Fig. 1A.

**B:** Phosphoamino acid analysis of the phosphorylated AXmito. Phosphorylated AXmito was extracted from the gel (Fig. 5A, lane b) and analyzed by thin layer electrophoresis as described in "Materials and Methods". Markers are phosphotyrosine (p-Tyr), phosphothreonine (p-Thr) and phosphoserine (p-Ser).

**C:** Phosphorylation of AXmito I by C-kinase. AXmito I was phosphorylated by C-kinase as described in the "Materials and Methods", and was analyzed autoradiographically after SDS-PAGE. a, in the absence of  $\text{Ca}^{2+}$  and phospholipid; b, in the presence of  $\text{Ca}^{2+}$  and phospholipid. SDS; PAGE, see legend to Fig. 1.

membrane-integrated PTK activities in human fibroblasts. The former could be dissociated by washing, but the latter could not. After the removal of the dissociable PTK from the membrane fraction, enough PTK activity retained to phosphorylate intrinsic substrates such as AXmito and a 300kDa peptide. The 35kDa peptide which was immuno-precipitated with anti-annexin I antibody was phosphorylated by intrinsic kinases (Fig. 5A). Since the 300kDa peptide was not immuno-precipitated by anti-annexin I antibody, this peptide was not immunologically related to annexin I, and further identification of this protein was not performed. The heavily phosphorylated

band with very high molecular weight observed in lanes b and c, as well as 26kDa phosphopeptide in lane b, were not identified either. The 35kDa peptide was extracted from the gel and subjected to phosphoamino acid analysis (Fig. 5B), and this assay revealed that AXmito was phosphorylated on tyrosine residue when mitochondrial respiration is stimulated by the addition of succinate which is a substrate for the Krebs cycle. The possible function of AXmito on the configurational change of mitochondria might be regulated by tyrosine phosphorylation in energetically stimulated mitochondria.

We have shown that annexin can be phosphorylated

by C-kinase with a better stoichiometry than PTK (about 1.0 mol Pi incorporated/mol protein by C-kinase as compared to 0.05–0.15 by PTK) (28). C-kinase could also phosphorylate AXmito (Fig. 5C). We analyzed the existence of C-kinase in mitochondria, but no activity of the enzyme was detected in Percoll-purified mitochondria (data not shown). C-kinase seems to be associated with the cytoplasmic side of the outer membrane in a Ca<sup>2+</sup>-dependent manner. In this respect, the phosphorylation of AXmito by C-kinase may not play a physiologically important role in mitochondria.

On the other hand, tyrosine phosphorylation might be physiological, because mitochondria express intrinsic PTK activity. Although much data concerning annexin phosphorylation has accumulated, and there is some evidence for the alteration of calcium sensitivity by PTK phosphorylation (44), the definite role of its phosphorylation remains unclear.

**Acknowledgements.** We acknowledge the generous gift of anti-annexin I and II antibodies from Dr. RB Pepinsky (Biogen Research Co., MA, USA). We are grateful to Dr. Najma Janjua for her proof-reading of this manuscript. We would like to express our appreciation to the staff of the Institute for Radioisotopes and the Common Equipment Research Center in the Kagawa Medical University for their technical assistance. This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan.

## References

- Huang KS, Wallner BP, Mattaliano RJ, Tizard R, Burne C, Frey A, Hession C, McGray P, Sinclair LK, Chow EP, Browning JL, Ramachandran KL, Tang J, Smart JE and Pepinsky RB: Two human 35 kd inhibitors of phospholipase A2 are related to substrates of pp60v-src and of the epidermal growth factor receptor/kinase. *Cell* (1986) **46**, 191–199.
- Pepinsky RB, Tizard R, Mattaliano RJ, Sinclair LK, Miller GT, Browning JL, Chow EP, Burne C, Huang KS, Pratt D, Wachter L, Hession C, Frey AZ and Wallner BP: Five distinct calcium and phospholipid binding proteins share homology with lipocortin I. *J Biol Chem* (1988) **263**, 10799–10811.
- Johnston PA, Perin MS, Reynolds GA, Wasserman SA and Sudhof TC: Two novel annexins from *Drosophila melanogaster*: Cloning, characterization, and differential expression in development. *J Biol Chem* (1990) **265**, 11382–11388.
- Gerke V: Identification of a homologue for annexin VII (synexin) in *Dictyostelium discoideum*. *J Biol Chem* (1991) **266**, 1697–1700.
- Smallwood M, Keen JN and Bowles DJ: Purification and partial sequence analysis of plant annexins. *Biochem J* (1990) **270**, 157–161.
- Creutz CE, Zaks WJ, Hamman HC, Crane S, Martin WH, Gould KL, Oddie KM and Parsons SJ: Identification of chromaffin granule-binding proteins. Relationship of the chromobindins to calelectrin, synhibin, and the tyrosine kinase substrates p35 and p36. *J Biol Chem* (1987) **262**, 1860–1868.
- Smith VL and Dedman JR: An immunological comparison of several novel calcium-binding proteins. *J Biol Chem* (1986) **261**, 15815–15818.
- Fauvel J, Salles JP, Roques V, Chap H, Rochat H and Douste-Blazy L: Lipocortin-like anti-phospholipase A2 activity of endonexin. *FEBS Lett* (1987) **216**, 45–50.
- Sudhof TC, Slaughter CA, Leznicki I, Barjon P, and Reynolds GA: Human 67-kDa calelectrin contains a duplication of four repeats found in 35-kDa lipocortins. *Proc Natl Acad Sci USA* (1988) **85**, 664–668.
- Saris CJ, Tack BF, Kristensen T, Glenney JR Jr and Hunter T: The cDNA sequence for the protein-tyrosine kinase substrate p36 (calpactin I heavy chain) reveals a multidomain protein with internal repeats. *Cell* (1986) **46**, 201–212.
- Shadle PJ, Gerke V and Weber K: Three Ca<sup>2+</sup>-binding proteins from porcine liver and intestine differ immunologically and physicochemically and are distinct in Ca<sup>2+</sup> affinities. *J Biol Chem* (1985) **260**, 16354–16360.
- Tait JF, Sakata M, McMullen BA, Miao CH, Funakoshi T, Hendrickson LE and Fujikawa K: Placental anticoagulant proteins: Isolation and comparative characterization four members of the lipocortin family. *Biochemistry* (1988) **27**, 6268–6276.
- William F, Mroczkowski B, Cohen S and Kraft AS: Differentiation of HL-60 cells is associated with an increase in the 35-kDa protein lipocortin I. *J Cell Physiol* (1988) **137**, 402–410.
- Fox MT, Prentice DA and Hughes JP: Increases in p11 and annexin II proteins correlate with differentiation in the PC12 pheochromocytoma. *Biochem Biophys Res Commun* (1991) **177**, 1188–1193.
- Wong WT, Frost SC and Nick HS: Protein-synthesis-dependent induction of annexin I by glucocorticoid. *Biochem J* (1992) **275**, 313–319.
- Cirino G and Flower RJ: Human recombinant lipocortin I inhibits prostacyclin production by human umbilical artery in vitro. *Prostaglandins* (1987) **34**, 59–62.
- Carey F, Forder R, Edge MD, Greene AR, Horan MA, Strijbos PJ and Rothwell NJ: Lipocortin I fragment modifies pyrogenic actions of cytokines in rats. *Am J Physiol* (1990) **259**, R266–R269.
- Perretti M: Lipocortin I and chemokine modulation of granulocyte and monocyte accumulation in experimental inflammation. *Gen Pharmacol* (1998) **31**, 545–552.
- Gerke V and Weber K: Identity of p36K phosphorylated upon Rous sarcoma virus transformation with a protein purified from brush borders; calcium-dependent binding to non-erythroid spectrin and F-actin. *Embo J* (1984) **3**, 227–233.
- Ikebuchi NW and Waisman DM: Calcium-dependent regulation of actin filament bundling by lipocortin-85. *J Biol Chem* (1990) **265**, 3392–3400.
- Burgoyne RD: Calpactin in exocytosis. *Nature* (1988) **331**, 20.
- Ohnishi M, Tokuda M, Masaki T, Fujimura T, Tai Y, Itano T, Matsui H, Ishida T, Konishi R, Takahara J and Hatase O: Involvement of annexin-I in glucose-induced insulin secretion in rat pancreatic islets. *Endocrinology* (1995) **136**, 2421–2426.
- Buckingham JC and Flower RJ: Lipocortin I: A second messenger of glucocorticoid action in the hypothalamo-pituitary-adrenocortical axis. *Mol Med Today* (1997) **3**, 296–302.
- Masaki T, Tokuda M, Ohnishi M, Watanabe S, Fujimura T, Miyamoto K, Itano T, Matsui H, Arima K, Shirai M, Maeba T, Sogawa S, Konishi R, Taniguchi K, Hatanaka Y, Hatase O and Nishioka M: Enhanced expression of the protein kinase substrate annexin II in human hepatocellular carcinoma. *Hepatology* (1996) **24**, 72–81.
- Pepinsky RB, Sinclair LK, Browning JL, Mattaliano RJ, Smart JE, Chow EP, Falbel T, Ribolini A, Garwin JL and Wallner BP: Purification and partial sequence analysis of a 37-kDa protein that inhibits phospholipase A2 activity from rat peritoneal exudates. *J Biol*

- Chem (1986) **261**, 4239–4246.
26. Davidson FF and Dennis EA: Biological relevance of lipocortins and related proteins as inhibitors of phospholipase A2. *Biochem Pharmacol* (1989) **38**, 3645–3651.
  27. Khanna NC, Hee-Chong M, Severson DL, Tokuda M, Chong SM and Waisman DM: Inhibition of phospholipase A2 by protein I. *Biochem Biophys Res Commun* (1986) **139**, 455–460.
  28. Khanna NC, Tokuda M and Waisman DM: Purification of three forms of lipocortin from bovine lung. *Cell Calcium* (1987) **8**, 217–228.
  29. Erikson E and Erikson RL: Identification of a cellular protein substrate phosphorylated by the avian sarcoma virus-transforming gene product. *Cell* (1980) **21**, 829–836.
  30. Fava RA and Cohen S: Isolation of a calcium-dependent 35-kilodalton substrate for the epidermal growth factor receptor/kinase from A-431 cells. *J Biol Chem* (1984) **259**, 2636–2645.
  31. Hatase O, Tokuda M, Itano T, Matsui H and Doi A: Purification and characterization of calmodulin from rat liver mitochondria. *Biochem Biophys Res Commun* (1982) **104**, 673–679.
  32. Hatase O, Itano T, Matsui H, Doi A, Etoh S, Nishio H and Nakahara S: A possible role for calmodulin in  $Ca^{2+}$ -induced swelling of mitochondria. *Biochem Int* (1987) **15**, 793–799.
  33. Etoh S, Matsui H, Tokuda M, Itano T, Nakamura M and Hatase O: Purification and immunohistochemical study of actin in mitochondrial matrix. *Biochem Int* (1990) **20**, 599–606.
  34. Lenting HB, Nicolay K and van den Bosch H: Regulatory aspects of mitochondrial phospholipase A2: Correlation of hydrolysis rates with substrate configuration as evidenced by  $^31P$ -NMR. *Biochim Biophys Acta* (1988) **958**, 405–415.
  35. De Winter JM, Korpancova J and van den Bosch H: Regulatory aspects of rat liver mitochondrial phospholipase A2: Effects of calcium ions and calmodulin. *Arch Biochem Biophys* (1984) **234**, 243–252.
  36. Nishida T, Inoue T, Kamiike W, Kawashima Y and Tagawa K: Involvement of  $Ca^{2+}$  release and activation of phospholipase A2 in mitochondrial dysfunction during anoxia. *J Biochem (Tokyo)* (1989) **106**, 533–538.
  37. Hatase O, Doi A, Itano T, Matsui H and Ohmura Y: A direct evidence of the localization of mitochondrial calmodulin. *Biochem Biophys Res Commun* (1985) **132**, 63–66.
  38. Tokuda M, Khanna NC, Arora AK and Waisman DM: Identification and characterization of the tyrosine protein kinases of rat spleen. *Biochem Biophys Res Commun* (1986) **139**, 910–917.
  39. Kikkawa U, Takai Y, Minakuchi R, Inohara S and Nishizuka Y: Calcium-activated, phospholipid-dependent protein kinase from rat brain. Subcellular distribution, purification, and properties. *J Biol Chem* (1982) **257**, 13341–13348.
  40. Tokuda M, Kong SK, Khanna NC and Waisman DM: Identification of a new in vitro substrate of tyrosine protein kinase. *Biochemistry* (1987) **26**, 5226–5229.
  41. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* (1970) **227**, 680–685.
  42. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* (1976) **72**, 248–54.
  43. Piedimonte G, Silvotti L, Chamaret S, Borghetti AF and Montagnier L: Association of tyrosine protein kinase activity with mitochondria in human fibroblasts. *J Cell Biochem* (1986) **32**, 113–123.
  44. Ando Y, Imamura S, Hong YM, Owada MK, Kakunaga T and Kannagi R: Enhancement of calcium sensitivity of lipocortin I in phospholipid binding induced by limited proteolysis and phosphorylation at the amino terminus as analyzed by phospholipid affinity column chromatography. *J Biol Chem* (1989) **264**, 6948–6955.

---

Received October 1, 1999; accepted December 2, 1999.